Johnson & Johnson $JNJ is Bard Financial Services Inc.’s 7th Largest Position

Bard Financial Services Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 99,786 shares of the company’s stock after selling 531 shares during the quarter. Johnson & Johnson comprises about 1.8% of Bard Financial Services Inc.’s holdings, making the stock its 7th biggest holding. Bard Financial Services Inc.’s holdings in Johnson & Johnson were worth $15,242,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Boltwood Capital Management lifted its position in shares of Johnson & Johnson by 16.9% during the 2nd quarter. Boltwood Capital Management now owns 4,042 shares of the company’s stock worth $617,000 after buying an additional 584 shares during the last quarter. Heartwood Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Heartwood Wealth Advisors LLC now owns 11,421 shares of the company’s stock worth $1,745,000 after buying an additional 352 shares during the last quarter. Legacy Private Trust Co. lifted its position in shares of Johnson & Johnson by 2.6% during the 2nd quarter. Legacy Private Trust Co. now owns 41,568 shares of the company’s stock worth $6,350,000 after buying an additional 1,050 shares during the last quarter. Gradient Investments LLC lifted its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Gradient Investments LLC now owns 222,172 shares of the company’s stock worth $33,937,000 after buying an additional 1,923 shares during the last quarter. Finally, Cultivar Capital Inc. lifted its position in shares of Johnson & Johnson by 16.4% during the 2nd quarter. Cultivar Capital Inc. now owns 6,043 shares of the company’s stock worth $923,000 after buying an additional 850 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $178.10 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40. The company’s fifty day moving average is $170.81 and its two-hundred day moving average is $161.27. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Bank of America upped their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. Finally, UBS Group upped their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.